Citrate-Based Constructs for Osteochondral Defect Repair
US-2024207485-A1 · Jun 27, 2024 · US
US2018250436A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2018250436-A1 |
| Application number | US-201615754508-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 6, 2016 |
| Priority date | Oct 16, 2015 |
| Publication date | Sep 6, 2018 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are a cell carrier for skin tissue regeneration using chitooligosaccharide and a method for producing the same. The cell carrier according to the present invention includes fish-derived collagen (FC), alginate (A), and chitooligosaccharide (COS1) of 1 to 3 kDa, and thus has excellent biocompatibility with dermal fibroblasts and has an excellent effect of being utilized as a cell carrier for skin tissue regeneration.
Opening claim text (preview).
1 . A method of preparing a cell carrier for skin tissue regeneration, the method comprising the steps of: (a) dissolving fish-derived collagen and alginate in 0.02 M acetic acid to prepare collagen-alginate (FCA) solution in a weight ratio (w/w) of 70:30; (b) freeze-drying the FCA solution obtained in step (a) to prepare a collagen-alginate (FCA) scaffold; (c) immersing the FCA scaffold obtained in step (b) in a cross-linker solution for 3 to 5 hours to cross-link the same; (d) adding 1 to 3 kDa chitooligosaccharide (COS1) in an amount of 0.5 to 5% (w/w) with respect to the total weight of the cross-linker solution and cross-linking the same for 20 to 30 hours while the FCA scaffold of step (c) is immersed in the cross-linker solution; and (e) immersing the FCA/COS1 cell carrier obtained in step (d) in distilled water for 48 hours, washing the cell carrier, and then freeze-drying the cell carrier. 2 . The method of claim 1 , wherein the cross-linker in step (c) includes one or more kinds selected from the group consisting of N,N′-carbonyldiimidazole (CDI), N,N′-dicyclohexylcarbonylimide (DCC), N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), 4-(4,6-dimethoxy-1,3,5-triazine)-4-methylmorpholium (DMT-MM), 2-benzotriazole-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (HODhbt), benzotriazol-1-oxy-tris-pyrrolidone-phosphonium hexafluorophosphate (PyBOP), benzotriazol-1-yl-oxy-tris-dimethylamino-phosphonium hexafluorophosphate (BOP), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), and N-hydroxysuccinimide (NHS). 3 . A cell carrier for skin tissue regeneration prepared according to the method of claim 1 . 4 . A cell carrier for skin tissue regeneration prepared according to the method of claim 2 .
Mixtures of macromolecular compounds · CPC title
Materials for use in artificial skin · CPC title
characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation · CPC title
Polysaccharides · CPC title
characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.